VERA Strangle Strategy
VERA (Vera Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
VERA (Vera Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.81B, a beta of 0.95 versus the broader market, a 52-week range of 18.76-56.05, average daily share volume of 1.2M, a public-listing history dating back to 2021, approximately 152 full-time employees. These structural characteristics shape how VERA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.95 places VERA roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on VERA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current VERA snapshot
As of May 15, 2026, spot at $37.11, ATM IV 69.70%, IV rank 18.70%, expected move 19.98%. The strangle on VERA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on VERA specifically: VERA IV at 69.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a VERA strangle, with a market-implied 1-standard-deviation move of approximately 19.98% (roughly $7.42 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated VERA expiries trade a higher absolute premium for lower per-day decay. Position sizing on VERA should anchor to the underlying notional of $37.11 per share and to the trader's directional view on VERA stock.
VERA strangle setup
The VERA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With VERA near $37.11, the first option leg uses a $38.97 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed VERA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 VERA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $38.97 | N/A |
| Buy 1 | Put | $35.25 | N/A |
VERA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
VERA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on VERA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on VERA
Strangles on VERA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VERA chain.
VERA thesis for this strangle
The market-implied 1-standard-deviation range for VERA extends from approximately $29.69 on the downside to $44.53 on the upside. A VERA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current VERA IV rank near 18.70% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on VERA at 69.70%. As a Healthcare name, VERA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to VERA-specific events.
VERA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. VERA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move VERA alongside the broader basket even when VERA-specific fundamentals are unchanged. Always rebuild the position from current VERA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on VERA?
- A strangle on VERA is the strangle strategy applied to VERA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With VERA stock trading near $37.11, the strikes shown on this page are snapped to the nearest listed VERA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are VERA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the VERA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 69.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a VERA strangle?
- The breakeven for the VERA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VERA market-implied 1-standard-deviation expected move is approximately 19.98%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on VERA?
- Strangles on VERA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VERA chain.
- How does current VERA implied volatility affect this strangle?
- VERA ATM IV is at 69.70% with IV rank near 18.70%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.